Ed Park is sincere and passionate about his calling as the CEO of Devoted Health, which provides Medicare Advantage plans to seniors in 29 states. But it remains to be seen if he can do more or the same with less.

The post CEO of For-Profit MA Plan Tells CMS “Pay Us Less” appeared first on MedCity News.

At the annual Medicarians conference in Las Vegas that draws brokers, agents, agency owners and field marketing organizations, among others, Dawn Maroney suggested that payers are not always the “bad guys.”

The post Alignment Health Plan CEO: Sometimes When MA Plan is Pulling Out, the Provider is to Blame appeared first on MedCity News.

A consultant who has analyzed healthcare policy over many decades declares that MA is in the middle of a fundamental reset both in terms of market headwinds and federal scrutiny.

The post Policy Expert Believes CMS is Taking “Adversial Posture” to Medicare Advantage appeared first on MedCity News.

Himanshu Shah, an activist investor and large shareholder of Novavax, whose stock has plummeted over the years, believes the company should cut costs more aggressively, reduce the size of its board, and do more to prop up its financial performance. But are the criticisms valid?

The post Is Shah Capital’s Criticism of Novavax Fair? A Wall Street Analyst Weighs In appeared first on MedCity News.

“We spend a lot of time focused on building the experiences that we think are the future of healthcare, and we don’t spend a heck of a lot of time worrying about what other people are doing,” declares Dan Caron, founder and CEO of Health Universe. Here’s a Q&A with the leader of the Kleiner Perkins-backed company.

The post CEO Building AI’s “Health Universe” Utterly Unperturbed By Rivals appeared first on MedCity News.

Fujifilm went from being the no. 1 camera film company to seeing sales tumble as consumers switched to digital cameras. Lars Petersen, CEO of the company’s biotechnologies business, explains how the company pivoted to becoming a partner of the life sciences industry.

The post MedCity Pivot Podcast: How Fujifilm Tackled An Existential Crisis appeared first on MedCity News.

Here are four perspectives from providers, patients, life science executives and healthcare technologists about ways to boost trust at a time of rapid AI deployments.

The post How to Boost Trust in Tech? 4 Perspectives from SXSW appeared first on MedCity News.

At SXSW, two FDA observers said stability is returning to the agency after painful DOGE personnel cuts last year, though it’s not equal across divisions. And now, AI tools are being adopted across the board to improve efficiency.

The post Which FDA Division Has the Most Stability As AI Tools Get Adopted Across the Agency? appeared first on MedCity News.

Mark Cuban, co-founder of Cost Plus Drugs, and Linda Yaccarino, CEO of the employer GLP-1 platform eMed Population Health, were at SXSW drawing a contrast between their approach to GLP-1 drugs and that of other direct-to-consumer companies. They also announced a collaboration where Cost Plus Drugs will be one of eMed’s distribution partners.

The post At SXSW, Cuban and eMed CEO Draw Contrast Between Them and Other “Marketing” Companies appeared first on MedCity News.

Brian Alexander feels the current system of drug development is shaped by biotech investor expectations. Valo Health is eschewing that path.

The post Valo Health CEO: We Don’t Want Investors To Drive the Science appeared first on MedCity News.

Shalin Shah, CEO of Marius Pharmaceuticals, which makes an oral testosterone replacement drug, thinks TRT therapy should no longer be regulated as a controlled substance

The post MedCity Pivot Podcast: Should Testosterone Replacement Therapy Be Less Regulated? appeared first on MedCity News.

The head of Anthropic’s biology and life sciences business spoke about introducing “first-party” products, having a presence inside the EHR and what Claude can do for rural hospitals.

The post Anthropic: It’s “Critical” To Bring Company Products to EHR appeared first on MedCity News.

Mayo Clinic has about 100 petabytes of structured and unstructured EHR data, and about 28 petabytes have been de-identified, but in the Mayo Clinic way. Now that data capability is being combined with institutional expertise to provide a compelling case for pharma companies looking to leverage data, AI and provider expertise in drug development.

The post COO of Mayo Clinic Platform Believes De-identified Data Leads to Loss of Utility for Pharma, Other Third Parties appeared first on MedCity News.

Elli Lilly has been in the news lately because of the announced $1 billion investment in a joint innovation lab with Nvidia, an AI powerhouse player. But AI drug discovery is only part of the story of where AI can be leveraged in biopharma.

The post Lilly’s Chief Information & Digital Officer: AI Use Goes Far Beyond Just Drug Discovery appeared first on MedCity News.

The CEO of the Israeli company believes the company has a superior, minimally invasive product that is designed to be a permanent implant, though the procedure is fully reversible.

The post Butterfly Medical Offers Non-Surgical Option to Treat Enlarged Prostate appeared first on MedCity News.

Jake Leach became DexCom’s chief executive on January 1 and is trying to write the turnaround story of this innovative medtech company. One story to tell is how CGMs should be a no-brainer for type 2 diabetes patients on GLP-1 weight loss drugs.

The post DexCom’s CEO Believes Diabetics On GLP-1s Should Also Wear CGMs appeared first on MedCity News.

People like Oprah Winfrey have struggled to maintain their weight loss after weaning themselves off GLP-1s. What if an outpatient medtech procedure did the trick?

The post What if Oprah Knew About Fractyl Health? appeared first on MedCity News.

The main question about health bots is accuracy and the trust or distrust that it engenders among users as a result. One journalist from the Washington Post and a strategic advisor to CMS had wildly differing experiences.

The post WaPo Columnist and CMS Official Provide Dueling Narratives of ChatGPT Health appeared first on MedCity News.

Jensen Huang, CEO of Nvidia and David Ricks, CEO of Eli Lilly, discussed their recently-announced partnership and the potential of GLP-1s at an event in San Francisco.

The post Nvidia CEO to Lilly CEO: You were running around the forest … appeared first on MedCity News.

Matthias Kleinz, executive vice president and head of translational sciences investments at UPMC Enterprises, explained why biopharma companies cannot ignore China anymore.

The post UPMC Enterprises’ Biopharma Lead: We are At a Tipping Point When it Comes to China appeared first on MedCity News.

Eliav Barr gave kudos to Eli Lilly for testing the company’s Zepbound weight loss drug in combination with a psoriatic arthritis drug to achieve better results for the underlying inflammation.

The post What Merck’s Chief Medical Officer Thinks of Lilly’s Approach to GLP-1s appeared first on MedCity News.

Executives from Merck, GE Healthcare and Alnylam Pharmaceuticals discuss past hurdles and how it has scrambled supply chains and clinical trial program. One warned about the effects of isolating China.

The post How Does Geopolitics Affect the Life Sciences Industry? 3 Executives Weigh In appeared first on MedCity News.

Dr. Jackie Gerhart firmly believes that an AI tool meant to help make sense of a person’s health or medical records must be housed within the EHR. She also contends that Epic’s digital concierge tool, Emmie, will do much more than simply reactively answer questions posed by the user.

The post What does Epic’s Chief Medical Officer Think About ChatGPT Health? appeared first on MedCity News.

In the fall of 2023, Microsoft demoed an AI tool at an industry conference designed to provide insights into a person’s medical record integrated within the EHR. But that’s the last I heard of it. Now OpenAI is seeking to fulfill the demand for personalized health information with ChatGPT Health.

The post ChatGPT Health: Is it a Missed Opportunity for Microsoft? appeared first on MedCity News.

Dr. Prajnan Das, department chair of Gastrointestinal (GI) Radiation Oncology at MD Anderson Cancer Center, talks about how precision medicine has evolved and how AI may actually be the technology that supercharges the conversion of the knowledge about human biology to personalized treatments that work.

The post How Precision Medicine and AI are Evolving: An MD Anderson Perspective appeared first on MedCity News.

The healthcare industry is contending with a difficult question: how to properly wield AI without taking on too much risk? Inherent in this battle is the role of humans. Here’s how Merck’s chief data officer is viewing AI.

The post For Merck, AI Puts Humans In the “Right Room” appeared first on MedCity News.

Dr. Iftach Dolev, a neuroscientist and CEO of QuantalX, explained how his company’s new FDA-cleared de novo device can bring a powerful tool to psychiatrists and neurologists alike. He claims this marks an important moment for brain health.

The post MedCity Pivot Podcast: Could This Device Make Managing Brain Health Easier? appeared first on MedCity News.

The CEOs of Nabla, Suki, Ambience Healthcare and Abridge separately spoke with MedCity News about why their products have staying power despite imminent competition from Epic.

The post Despite Competition, All Big 4 Ambient AI Company CEOs Believe They Will Succeed appeared first on MedCity News.

The billionaire Mark Cuban whose Cost Plus Drugs company has been shaking up the world of prescription drug coverage minces no words when it comes to the role of employers in bringing down healthcare costs. But some employers believe he is wrong.

The post Is Mark Cuban Wrong About Employers, PBMs and Drug Prices? appeared first on MedCity News.

Dr. Rowland Illing explained how life science companies and health systems are leveraing AWS HealthLake to transform healthcare.

The post MedCity Pivot Podcast: A Chat With AWS Chief Medical Officer Rowland Illing appeared first on MedCity News.